Status:
UNKNOWN
Probiotics in NASH Patients - PROBILIVER TRIAL
Lead Sponsor:
Hospital de Clinicas de Porto Alegre
Conditions:
Non-Alcoholic Fatty Liver Disease
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Non-alcoholic Fatty Liver Disease (NAFLD) is characterized by excessive accumulation of lipids in hepatocytes, not associated with alcohol consumption and ranges from hepatic steatosis to steatohepati...
Detailed Description
In this randomized clinical trial (RCT) will include adult outpatients linked to the Gastroenterology Service of the Hospital de Clínicas de Porto Alegre (Hospital of Clinics of Porto Alegre-HCPA) -Br...
Eligibility Criteria
Inclusion
- adult outpatient with diagnostic of NAFLD
Exclusion
- HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV) infected patients
- significant intake of alcohol
- cirrhosis,
- pregnant women,
- transplanted patients,
- intake of supplements or foods containing probiotics,
- immunosuppressants, antibiotics, corticosteroids, valproic acid and amiodarone,
- other chronic inflammatory diseases
Key Trial Info
Start Date :
November 29 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 20 2021
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT03467282
Start Date
November 29 2017
End Date
December 20 2021
Last Update
June 19 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital de Clinicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil, 90035003